EBAG9 modulates host immune defense against tumor formation and metastasis by regulating cytotoxic activity of T lymphocytes

T Miyazaki1, K Ikeda1, K Horie-Inoue1, T Kondo2, S Takahashi3 and S Inoue1,4,5

Estrogen receptor-binding fragment-associated antigen 9 (EBAG9) is a primary estrogen-responsive gene that we previously identified in MCF-7 breast cancer cells using the CpG genomic binding-site cloning technique. The expression of EBAG9 protein is often upregulated in malignant tumors, suggesting that this protein is involved in cancer pathophysiology. In the present study, we investigated the role of EBAG9 in host defense against implanted tumors in Ebag9-knockout (Ebag9KO) mice. MB-49 mouse bladder cancer cells were subcutaneously implanted into Ebag9KO and control mice. We found that tumor formation and metastasis to the lung by MB-49 cells were substantially reduced in Ebag9KO mice compared with control mice. The infiltration of CD8+, CD3+ and CD4+ T cells into the generated tumors was enhanced in Ebag9KO mice compared with controls. Notably, CD8+ T cells isolated from tumors in Ebag9KO mice exhibited substantial upregulation of immunity- and chemotaxis-related genes, including interleukin-10 receptor, interferon gamma, granzyme A, granzyme B, and chemokine (C-X-C motif) receptor 3 compared with CD8+ T cells from tumors in control mice. The CD8+ T cells isolated from tumors in Ebag9KO mice also exhibited enhanced degranulation and increased cytolytic activity. Furthermore, the adoptive transfer of CD8+ T cells isolated from tumors in Ebag9KO host could repress tumor growth by MB-49 cells implanted in wild-type host. These results suggest that EBAG9 modulates tumor growth and metastasis by negatively regulating the adaptive immune response in host defense. EBAG9 could be a potential target for tumor immunotherapy.

INTRODUCTION

Estrogen receptor-binding fragment-associated antigen 9 (EBAG9) is an estrogen-responsive gene that was originally isolated from a CpG island library of MCF-7 human breast cancer cells using a genomic binding-site cloning method.1 EBAG9 is expressed in estrogen target organs as well as several other organs including the brain, liver, heart and kidney.2 EBAG9 expression can be induced by estrogen, as observed in cell lines and in ovariectomized mice treated with 17β-estradiol. Although the physiological function of EBAG9 has not been well defined, the molecule may be implicated in cancer pathophysiology based on protein expression studies in breast,3 ovarian,4 prostate,5 hepatocellular,6 renal cell7 and bladder cancers.8 Furthermore, it has been shown that the immunoreactivity of EBAG9 positively correlates to advanced tumor grades and poor prognosis.3–9 Therefore, EBAG9 is assumed to promote the progression of malignant tumors.

It has been reported that EBAG9 is localized in the Golgi apparatus and increases O-linked glycan expression.10 The O-linked glycans, sialyl-Tn, is a carbohydrate antigen overexpressed in several epithelial cancers.11 It has been shown that sialyl-Tn expression and concomitant changes in the overall O-glycan profile lead to a decreased adhesion and increased migration of MDA-MB-231 breast cancer cells. sialyl-Tn-positive MDA-MB-231 clones exhibit increased tumor growth in severe combined immunodeficiency mice.11

We have previously shown that EBAG9 has no significant effect on proliferation of Renca cells in vitro, whereas EBAG9 overexpression in Renca cells promotes tumor formation in vivo when the cells are implanted in BALB/c mice. Interestingly, in immunodeficient BALB/c nude mice, tumors generated by EBAG9-overexpressing Renca cells and vector-expressing Renca cells had similar volumes. Thus, EBAG9 is assumed to be a tumor-promoting factor rather than an essential oncoprotein by itself. The difference between EBAG9-overexpressing and vector-expressing Renca cells in terms of tumor growth in BALB/c mice could be owing to reduced numbers of infiltrating CD8+ T cells in EBAG9-overexpressing Renca cell tumors, as a result of suppression of antitumor immunity in the micromilieu.7

Cytotoxic T lymphocytes exclude tumor cells by releasing secretory lysosomes, which contain granzymes and perforin. These lysosomes are produced in the endoplasmic reticulum and subsequently transported to the Golgi complex.12 It has been shown that the absence of EBAG9 enhances the cytotoxic activity of CD8+ T cells in EBAG9-knockout mice. Although the absence of EBAG9 did not affect lymphocyte development, it led to an increased secretion of granzyme A from cytotoxic T lymphocytes.

1Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan; 2KAST, Project on Health and Anti-aging, Kanagawa, Japan; 3Department of Anatomy and Embryology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan; 4Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; and 5Department of Anti-Aging Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Correspondence: Professor S Inoue, Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

E-mail: INOUE-GER@h.u-tokyo.ac.jp
Received 18 August 2014; revised 22 September 2014; accepted 30 September 2014
EBAG9 as a modulator of antitumor immunity
T Miyazaki et al

RESULTS

Generation of Ebag9KO mice

To assess the physiological function of EBAG9 in host defense against tumors, we generated Ebag9-knockout (Ebag9KO) mice by the following steps. We first generated Ebag9fl/fl mice by homologous recombination in embryonic stem cells (Figure 1a). Then, Ebag9 fl/fl mice were crossed with Ayu1-Cre mice, which ubiquitously expressed Cre recombinase,14 to remove the neomycin-resistance cassette (bottom), the resulting offspring has a heterozygous deletion of Ebag9 (Figure 1b). To confirm the absence of full-length Ebag9 mRNA and protein expression in Ebag9KO mice, we examined Ebag9 expression in mouse embryonic fibroblasts (MEFs) using quantitative real-time PCR (qRT–PCR) (Figure 1c) and western blot analysis (Figure 1d). Furthermore, we confirmed whether full-length Ebag9 mRNA was deleted in brain, liver, spleen, bone marrow and thymus in Ebag9KO and control Ebag9fl/fl–Ayu1-Cre mice using qRT–PCR (Figure 1e). The expression of full-length Ebag9 mRNA and protein was completely abolished in Ebag9KO MEFs and tissues (including brain, liver, spleen, bone marrow and thymus). Ebag9KO mice seemed to be healthy and fertile without any apparent morphological abnormalities. In addition, mating of Ebag9KO mice produced normal litters.

Loss of Ebag9 in host suppresses tumor growth and lung metastasis by MB-49 bladder cancer cells

We investigated the role of EBAG9 in host tumor immunity using Ebag9KO mice with implanted tumors. MB-49 bladder cancer cells, which originated from a carcinogen-induced tumor of bladder epithelial origin in male C57BL/6 mice,15 were inoculated into Ebag9KO and control mice. MB-49 cells developed smaller tumors in Ebag9KO mice than in control mice 4 weeks after inoculation (Figures 2a and b). After 4 weeks, the volume of tumors was significantly smaller in Ebag9KO mice than in control mice (2733 ± 1216 versus 5218 ± 1895 mm3, n = 8, P < 0.01) (Figure 2c). Furthermore, to determine whether loss of EBAG9 is also involved in tumor metastasis, we investigated lung tissue in Ebag9KO and control mice. Tumor metastasis to the lung was significantly reduced in Ebag9KO mice compared with control mice (Figures 3a and b). After 4 weeks, the number of metastatic foci in the lung was significantly lower in Ebag9KO mice than in control mice (2.63 ± 2.39 versus 10.50 ± 3.39; Ebag9KO mice, n = 8; control mice, n = 6; P < 0.01) (Figure 3c). These results indicate that EBAG9 is involved in tumor growth and metastasis in vivo.

treated with CD3 antibody. EBAG9 is considered to inhibit endosomal-lysosomal trafficking of cytotoxic effectors.13

To assess the functional relevance of EBAG9 in host defense against tumors, we generated Ebag9-knockout (Ebag9KO) mice by crossing Ebag9fl/fl mice with Ayu1-Cre mice, which ubiquitously express Cre recombinase.14 We show that Ebag9KO mice exhibit strong antitumor immune responses including tumor suppression of lung metastasis. Notably, in Ebag9KO mice, CD8+ T-cell infiltration is significantly increased in generated tumors. We show that CD8+ T cells in Ebag9KO mice exhibit increased expression of interleukin-10 receptor (Il10r), interferon gamma (Ifng), granzyme A (Gzma), granzyme B (Gzmb) and chemokine (C-X-C motif) receptor 3 (Cxcr3), as well as increased degranulation and cytotoxic activity. Moreover, adoptively transferred CD8+ T cells isolated from tumors generated in Ebag9KO mice suppress tumor growth in wild-type mice.
Increased infiltration of CD8\(^\text{+}\), CD3\(^\text{+}\), and CD4\(^\text{+}\) T cells in implanted tumors of Ebag9KO mice

To explore whether EBAG9 modulates the subtype-specific reactivity of T cells against tumors, we examined the number of tumor-infiltrating T cells in the tumors generated in Ebag9KO and control mice by immunohistochemistry using antibodies specific for CD8, CD3, and CD4. Significant increases in the number of CD8\(^\text{+}\) T cells (56.17 ± 22.05 versus 10.33 ± 11.07; \(P = 0.01\)) (Figure 4a), CD3\(^\text{+}\) T cells (225.40 ± 39.06 versus 177.92 ± 31.87; Ebag9KO mice, \(n = 8\); control mice, \(n = 6\); \(P < 0.01\)) (Figure 4b), and CD4\(^\text{+}\) T cells (62.32 ± 27.83 versus 42.91 ± 21.06; Ebag9KO mice, \(n = 8\); control mice, \(n = 6\); \(P < 0.05\)) (Figure 4c) in implanted tumors were observed in Ebag9KO mice.

![Figure 2](image2.png)

**Figure 2.** Reduced tumor growth of MB-49 bladder cancer cells implanted in Ebag9KO mice. MB-49 cells (5 × 10\(^5\) cells per mouse) suspended in 50 μl of PBS were injected with 50 μl of Matrigel into the right flanks of Ebag9KO and control mice. Mice were sacrificed 28 days after implantation and tumors were excised. Representative photographs of control (a) and Ebag9KO mice (b) 4 weeks after inoculation with tumor cells. (c) Tumor volume in Ebag9KO mice is significantly smaller than that in control mice (\(n = 8\) each). The data shown are mean values ± s.d. \(*P < 0.01\) by Student's t-test.

Upregulation of expression of immunity- and chemoattraction-related genes in CD8\(^\text{+}\) T cells isolated from tumors generated in Ebag9KO mice

To investigate the role of EBAG9 in CD8\(^\text{+}\) T-cell-mediated immune surveillance, we examined the expression of immunity- and chemoattraction-related genes in CD8\(^\text{+}\) T cells isolated from tumors generated in Ebag9KO and control mice. The expression of Il10r (Figure 5a), Ifng (Figure 5b), Gzma (Figure 5c), Gzmb (Figure 5d), and Cxcr3 (Figure 5e) was upregulated in CD8\(^\text{+}\) T cells isolated from tumors generated in Ebag9KO mice compared with control mice (each \(n = 3\), \(P < 0.05\)). We also confirmed that there was no detectable expression of full-length Ebag9 mRNA (Figure 5f) in the CD8\(^\text{+}\) T cells isolated from tumors generated in Ebag9KO and control mice, we stained the isolated cells with anti-CD8a-FITC antibody and analyzed the cells by flow cytometry. CD8\(^\text{+}\) T cells typically constituted >90% of the isolated cells (data not shown). These results indicate that loss of Ebag9 resulted in the upregulation of genes related to cytotoxicity and chemoattraction.

Loss of EBAG9 induces host immune surveillance

We next performed a degranulation assay (Figure 6a) and a cytotoxicity assay (Figure 6b) to investigate whether the loss of Ebag9 expression influenced the activity of CD8\(^\text{+}\) T cells. CD8\(^\text{+}\) T cells isolated from tumors generated in Ebag9KO mice exhibited increased degranulation and cytotoxicity, suggesting that the loss of EBAG9 contributes to the fusion of lysosomes with the plasma membrane in CD8\(^\text{+}\) T cells. Furthermore, we investigated whether the CD8\(^\text{+}\) T cells isolated from tumors generated in Ebag9KO mice are involved in the suppression of bladder cancer MB-49 tumor growth. We intravenously transferred CD8\(^\text{+}\) T cells isolated from tumors generated in Ebag9KO or control mice into C57BL/6 mice. Then, MB-49 cells were inoculated into the recipient mice. Adaptively transferred CD8\(^\text{+}\) T cells isolated from tumors generated in Ebag9KO mice suppressed tumor growth of MB-49 cells (Figures 6c and d). After 13 days, adaptive transfer of CD8\(^\text{+}\) T cells from Ebag9KO mice significantly inhibited tumor growth in C57BL/6 mice compared with those from control mice (333.9 ± 183.3 versus 616.5 ± 107.3 mm\(^3\); Ebag9KO mice, \(n = 5\); control mice, \(n = 7\); \(P < 0.01\)) (Figure 6e).

**DISCUSSION**

In the present study, we demonstrated that tumor formation and lung metastasis by implanted MB-49 mouse bladder cancer cells were substantially reduced in Ebag9KO mice compared with...
EBAG9 as a modulator of antitumor immunity

Figure 4. Increased numbers of CD8+, CD3+ and CD4+ T cells in tumors generated in Ebag9KO mice. Paraffin sections of tumors generated in Ebag9KO and control mice were blocked in 0.3% H2O2 and incubated with specific antibodies for CD8 (a), CD3 (b) or CD4 (c). Sections were then incubated with antirabbit EnVision+ reagent and counterstained with hematoxylin. Tumor-infiltrating lymphocytes positive for CD8 (a), CD3 (b) or CD4 (c) expression were microscopically counted in a high-power field of view at a magnification of 400× (Ebag9KO, n = 8; control, n = 6). The data shown in lower panels are mean values ± s.d. *P < 0.05; **P < 0.01 by Student’s t-test. Scale bar, 20 μm.

control mice. Notably, in Ebag9KO mice, the numbers of infiltrating CD8+, CD3+ and CD4+ T cells were significantly increased in tumors derived from MB-49 cells, and the expression of immunity- and chemoattraction-related genes was upregulated in CD8+ T cells isolated from these tumors. EBAG9 was also found to be involved in the regulation of lysosome-mediated degranulation and cytotoxic activity of CD8+ T cells. Furthermore, the adoptive transfer of CD8+ T cells isolated from tumors in Ebag9KO host could repress tumor growth by MB-49 cells implanted in wild-type host. These results suggest that EBAG9 acts as a negative regulator of CD8+ T cells in host immune surveillance against tumors.

In antitumor immunity, T-cell-mediated immune surveillance is a main host defense mechanism. In this context, IL-10 is assumed to be an immunosuppressive cytokine within the tumor microenvironment. Recent studies have revealed, however, that IL-10 has rather diverse functions, as the molecule also induces potent antitumor responses. It has been shown that IL-10 induces the proliferation and cytotoxic activity of CD8+ T cells and functions as a chemoattractant for CD8+ T cells. Here we have shown that the loss of EBAG9 enhances antitumor responses in CD8+ T cells, as these cells exhibited higher expression of Il10r in Ebag9KO mice than in controls. IL-10 activates CD8+ T cells in vitro, and treatment with IL-10 leads to tumor rejection in multiple tumor-bearing mouse models. IL-10 also increases the expression of IL-10R in activated CD8+ T cells. Furthermore, IL-10 treatment induces expression of interferon-γ (IFN-γ) by CD8+ T cells, which in turn increases levels of chemokines, such as CXCL9 (monokine induced by interferon, or MIG) and CXCL10 (interferon-induced protein of 10 kDa, or IP-10), in the tumor and serum. These chemokines act as chemoattractants for T cells, suggesting a positive feedback loop of IFN-γ-producing CD8+ T-cell recruitment into the tumor, initiated by IL-10. Indeed, such a feedback loop was proposed for mice bearing mammary tumors and treated with IL-10. Overall, these results suggest that EBAG9 in CD8+ T cells may act as a negative regulator of antitumor responses and that loss of EBAG9 function results in the activation of IL-10/IL-10R signaling.

CXCR3 is an inflammatory chemokine receptor present on activated T cells, particularly CD4+ T cells and CD8+ T cells. CXCR3 has an important role in T-cell trafficking and function. Chemokines such as CXCL9, CXCL10 and CXCL11 function as CXCR3 ligands that induce cell migration. It has been reported that these chemokines are abundantly expressed in CXCR3-positive cells involved in human and mouse cancers. We have shown here that the expression of Ifng and Cxcr3 is upregulated in Ebag9-deficient CD8+ T cells. Our findings suggest that EBAG9 could be a negative regulator of cytotoxic activity and chemotraction of T cells, resulting in the suppression of tumor immunosurveillance.

Degranulation of mature antigen-specific CD8+ T cells is a requisite process for perforin- and granzyme-mediated killing of target cells. We found that the loss of EBAG9 increased the expression of a degranulation marker, CD107, in CD8+ T cells that had infiltrated tumors. This suggests that EBAG9 is involved in the regulation of endosomal trafficking of lytic granules in tumor-infiltrating T cells. Our findings are consistent with a previous report that EBAG9 deficiency increased the release of lytic granule contents and enhanced cytolytic capacity.

We assume that the enhanced degranulation activity of CD8+ T cells will primarily contribute to the magnitude of tumor inhibitory effects of Ebag9KO host in this study. We also consider that CD8+ T cells with increased degranulation activity will secrete more amounts of cytokines and chemokines, such as IL-10, which lead to further chemoattraction of CD8+ T cells and other immune-related cells into the tumors. The number of infiltrating effector cells can be another major important factor for the magnitude of antitumor immunity, if the secretion of lytic
granules from CD8+ T cells is stable and the cell frequency is a unique factor for the total amount of cytolytic activity.

In summary, our results show that EBAG9 is a critical factor that regulates T-cell-mediated antitumor immunity in vivo. Given these results and our previous findings regarding EBAG9 overexpression in cancers, we conclude that EBAG9 contributes to the promotion of tumor proliferation and the reduction of tumor immune surveillance. The management of EBAG9 expression in both tumors and their microenvironment could be an alternative therapeutic option for advanced stages of cancers.

MATERIALS AND METHODS

Reagents
Human anti-EBAG9 monoclonal antibody was generated against a glutathione S-transferase-EBAG9 fusion protein. Antibodies against CD3 (Dako, Tokyo, Japan), CD4 (H-370; Santa Cruz Biotechnology, Dallas, TX, USA), CD8a (H-160; Santa Cruz Biotechnology), CD107-PE (1D4B; BD Reagents), and CD11c (BD Pharmingen, Tokyo, Japan), CD8a–FITC (53-6.7; BD Pharmingen) and anti–β-actin (AC-74; Sigma-Aldrich, Tokyo, Japan) were purchased.

Bladder cancer cells
MB-49 mouse bladder cancer cells, which originated from a carcinogen-induced tumor of bladder epithelial origin in male C57BL/6 mice, were maintained in RPMI 1640 containing 10% fetal calf serum, penicillin (50 U/ml), and streptomycin (50 mg/ml).

Generation of Ebag9KO mice
To generate Ebag9fllox/− (Ebag9fl/fl) mice, genomic DNA covering the Ebag9 locus was obtained from a 129SVJ mouse genomic library (Agilent Technologies, Santa Clara, CA, USA) by screening with a mouse Ebag9 cDNA probe. The resulting DNA fragments were assembled into a targeting vector in which the Venus gene was inserted in frame at the translation initiation codon of the Ebag9 gene and exon 2 was floxed by loxP sites (Figure 1a). After linearization, the targeting vector was electroporated into E14 embryonic stem cells. G418-resistant colonies were selected and analyzed for homologous recombination by PCR and Southern blot hybridization. The primers for the PCR screening were 5′-GGACACAGACAGATTGCACATCGAGCA-3′ and 5′-TTGGTGTCAGTGGGACATCGAGCA-3′. Positive clones were verified by Southern blot hybridization in which genomic DNA digested with PvuII was probed with a 414-bp DNA fragment corresponding to the 5′ upstream region of the Ebag9 gene. The correctly targeted embryonic stem cells were injected into C57BL/6 blastocysts and transferred into pseudopregnant females. Chimeric offspring were bred to C57BL/6 mice expressing the Cre recombinase gene under the control of the ubiquitous Ayu1 promoter (Ayu1-Cre). Genotypes were determined by PCR analysis of tail DNA (Figure 1b). For amplification of the wild-type allele, the sense and antisense primers A (5′-GGGAAATCTACTTTGCTGCGC-3′) and B (5′-CAGCTGAAGTATGTGCC-3′) were used (Figure 1a). For genotyping of Ayu1-Cre mice, primers derived from Cre (5′-CTCTGAAAACTGCTTCTGCAGTCAGG-3′ and 5′-GAGTGCATAGCTGGGTGGAGCAGATG-3′) were used to amplify a 633-bp product. Mice were kept under specific pathogen-free conditions and fed dry food and water ad libitum. All experiments were performed according to the guidelines for the care and use of laboratory animals of both the University of Tsukuba and Saitama Medical University.

Quantitative real-time PCR
Total RNAs were extracted from MEFs, brain, liver, spleen, bone marrow, thymus and CD8+ T cells of Ebag9KO and control mice using ISOGEN reagent (Nippon Gene, Tokyo, Japan), and first-stand cDNA was generated with 1 μg of total RNA using SuperScript III reverse transcriptase (Invitrogen, San Diego, CA, USA) and oligo(dT)12 primer. To evaluate the expression of mouse Ebag9, Cdx8, Il10r, Ifng, Gzma, Gzmb, and Cxcr3 mRNA, RT-PCR was done using primers specific for mouse Ebag9 (sense, 5′-TGGGGAATTCATGAGTCACATG-3′; antisense, 5′-GTCCTGTTCTGGGTGTCTC-3′), Cdx8 (sense, 5′-GGTGGCGACCGAGCTCA-3′; antisense, 5′-TTGGTTCCTGTTCTGGGTGTCTC-3′), Il10r (sense, 5′-TGGGGAATTCATGAGTCACATG-3′; antisense, 5′-GTCCTGTTCTGGGTGTCTC-3′), Gzma (sense, 5′-TGACTGTGTCCTGACACTGA-3′; antisense, 5′-CGGACTCATGTTGCCTGACACTGA-3′), Gzmb (sense, 5′-GGTGGCGACCGAGCTCA-3′; antisense, 5′-GTCCTGTTCTGGGTGTCTC-3′), Il10r (sense, 5′-TGGGGAATTCATGAGTCACATG-3′; antisense, 5′-GTCCTGTTCTGGGTGTCTC-3′), Cxcr3 (sense, 5′-CGGACTCATGTTGCCTGACACTGA-3′; antisense, 5′-GTCCTGTTCTGGGTGTCTC-3′), and Ifng (sense, 5′-TTGGTTCCTGTTCTGGGTGTCTC-3′; antisense, 5′-GTCCTGTTCTGGGTGTCTC-3′). Mice Gpox was placed as an internal control. The results are shown as mean values ± s.d. Statistical analysis was carried out using Student’s t-test.
Figure 6. Promotion of degranulation and cytotoxic activity of CD8+ T cells by EBAG9 knockout. (a) Flow cytometry-based degranulation assay of CD8+ T cells from tumors in control (left) and Ebag9KO (middle) mice using phycoerythrin (PE)-conjugated anti-CD107 antibody. Overlay (right) of anti-CD107-PE fluorescence in Ebag9KO and control CD8+ T cells illustrates the significant increase in degranulation due to Ebag9 deletion. The peaks with grey shading represent cells stained with IgG2a–PE as a negative control. (b) Cytotoxicity assay of CD8+ T cells from tumors in Ebag9KO and control mice. MB-49 cells (target) were incubated with CD8+ T cells (effector) prepared from tumors generated in Ebag9KO and control mice at various effector/target ratios. The cytotoxic activity of CD8+ T cells was monitored as the amount of lactate dehydrogenase in culture medium using the CytoTox 96 Non-Radioactive Cytotoxicity Assay. (c) and (d) CD8+ T cells isolated from tumors generated in Ebag9KO mice exhibits antitumor activity. C57BL/6 mice were intravenously injected the CD8+ T cells (2 × 10^6 cells per mouse) isolated from tumors generated in control (c) or Ebag9KO mice (d) and 2 days later, MB-49 cells were subcutaneously implanted into the recipient mice (5 × 10^5 cells per mouse). Tumor volumes were calculated once or twice a week. (e) Adaptive transfer of CD8+ T cells from Ebag9KO mice significantly suppressed tumor growth by MB-49 cells implanted in C57BL/6 mice compared with those from control mice. The data shown are mean values ± s.d. *P < 0.05, **P < 0.01 by Student’s t-test.
Western blot analysis
Cells were suspended in lysis buffer (20 mM HEPES, pH 7.9, 300 mM NaCl, 1 mM EDTA, 15% glycerol, 0.5% Nonidet P-40, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride), rocked gently for 50 min at 4 °C, and centrifuged at 14,000 × g for 5 min at 4 °C. The supernatants were used as cell lysates. Cell lysates were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis and electrothermally transferred onto polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). Membranes were probed with mouse anti-EBAG9 antibody or anti-β-actin monoclonal antibody.

In vivo tumor challenge
For subcutaneous implantation, MB-49 bladder cancer cells (5 × 10^6 cells per mouse) suspended in 50 μl of PBS were injected with 50 μl of Matrigel (Becton Dickinson, San Jose, CA, USA) into the flanks of Ebag9KO and control mice. Tumor volume was calculated three times a week. Mice were flamed with 5% CO2 (Becton Dickinson, San Jose, CA, USA) into the per mouse) suspended in 50 μl M EDTA, 15% glycerol, 0.5% Nonidet P-40, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, rocke gently for 50 min at 4 °C, and centrifuged at 14,000 × g for 5 min at 4 °C. The supernatants were used as cell lysates. Cell lysates were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis and electrothermally transferred onto polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). Membranes were probed with mouse anti-EBAG9 antibody or anti-β-actin monoclonal antibody.

Immunohistochemistry
Immunohistochemical studies were done using the streptavidin–biotin amplification method with horseradish peroxidase detection. Paraffin sections of tumors were blocked in 0.3% H2O2 (15 min) and incubated overnight with specific antibodies against CD3, CD4 or CD8 for bladder cancer tumors (1:200 dilution). Sections were incubated with antirabbit EnVisions+ reagent (Dako) and counterstained with hematoxylin (Wako, Tokyo, Japan). The numbers of tumor-infiltrating lymphocytes positive for CD8, CD3 or CD4 expression were microscopically examined in the high-power field of view at a magnification of 400 ×. A spleen specimen from a control mouse was used as a positive control.

CD8+ T-cell isolation
Mouse CD8+ T cells were isolated from tumor tissue using a mouse CD8-positive selection kit (STEMCELL Technologies, Vancouver, BC, Canada), according to the manufacturer’s protocol. Isolated CD8+ T cells were activated and expanded using a T-cell activation/expansion kit (Miltenyi Biotec, Bergisch Gladbach, Germany).

Degranulation assay
CD8+ T cells isolated from tumors generated in Ebag9KO and control mice were washed with PBS and fixed with 70% ethanol. Cells were then washed and resuspended in FACS buffer (10 mM HEPES (pH 7.4), 140 mM NaCl, 2.5 mM CaCl2) in the presence of anti-CD107a or IgG2a conjugated with PE. Degranulation was evaluated by flow cytometry and calculated as the percentage of cells that showed an increase in CD107a membrane fluorescence.

Cytotoxicity assay
MB-49 mouse bladder cancer cells were used as target cells. Target cells were incubated with effector CD8+ T cells isolated from tumors generated in Ebag9KO and control mice at various effector/target ratios in a final volume of 100 μl for 8 h at 37 °C. Lactate dehydrogenase released from cells with damaged membranes was examined using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI, USA) and absorbance was measured at 490 nm. Experiments were done in triplicate. The results are shown as mean values ± s.d. Statistical analysis was carried out using Student’s t-test.

Adaptive CD8+ T-cell transfer
Mouse CD8+ T cells were isolated from tumor tissue in Ebag9KO and control mice using mouse CD8-positive selection kit (STEMCELL Technologies). The CD8+ T cells were intravenously injected into C57BL/6 mice (2 × 10^6 cells per mouse), after 2 days, the mice were inoculated with MB-49 cells (5 × 10^6 cells per mouse) that were suspended in 50 μl of PBS with 50 μl of Matrigel into the flank. Tumor volume was measured once or twice a week. The results are shown as mean values ± s.d. Statistical analysis was carried out using Student’s t-test.
et al. 27 Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Kundu N, Beaty TL, Jackson MJ, Fulton AM. Antimetastatic and antitumor activities of Emmerich J, Mumm JB, Chan IH, LaFace D, Truong H, McClanahan T. J Immunol 2000; 174: 4729–4737.

28 Jinguan T, Larsen CG, Gesser B, Matsushima K, Thurstrup-Pedersen K. Human IL-10 is a chemottractant for CD8+ T lymphocytes and an inhibitor of IL-8-induced CD4+ T lymphocyte migration. J Immunol 1993; 151: 4545–4551.

29 Chen WF, Zlotnik A. IL-10: a novel cytotoxic T cell differentiation factor. J Immunol 1991; 147: 528–534.

30 Halak BK, Maguire HC Jr, Lattime EC. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res 1999; 59: 911–917.

31 Gerard CM, Bruyns C, Delvaux A, Baudson N, Dargent JL, Goldman M et al. Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells. Hum Gene Ther 1996; 7: 23–31.

32 Emmerich J, Mumm JB, Chan IH, LaFace D, Truong H, McClanahan T et al. IL-10 directly activates and expands tumor-resident CD8+ T cells without de novo infiltration from secondary lymphoid organs. Cancer Res 2012; 72: 3570–3581.

33 Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996; 184: 963–969.

34 Kundu N, Beatty TL, Jackson MJ, Fulton AM. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst 1996; 88: 536–541.

35 Loetscher M, Loetscher P, Brass N, Meese E, Moser B. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 1998; 28: 3696–3705.

36 Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187: 2009–2021.

37 Lu B, Humbles A, Bota D, Gerard C, Moser B, Soler D et al. Structure and function of the murine chemokine receptor CXCR3. Eur J Immunol 1999; 29: 3804–3812.

38 Beckamp KL, Figlin RA, Moldawer N, Pantuck AJ, Belledgeun AS, Burdick MD et al. Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy. J Immunother 2007; 30: 417–424.

39 Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM et al. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 2007; 67: 3396–3405.

40 Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009; 69: 3077–3085.

41 Jones D, Benjamin RJ, Shahsafaie A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 2000; 95: 627–632.

42 Narvaeza I, Mazzolini G, Barajas M, Duarte M, Zaratiegui M, Qian C et al. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol 2000; 164: 3112–3122.

43 Pan J, Burdick MD, Belperio JA, Xue YY, Gerard C, Sharma S et al. CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunangiostasis. J Immunol 2006; 176: 1436–1446.

44 Peters PJ, Bonst J, Oorschot V, Fukuda M, Krabenhuihl O, Tschopp J et al. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp Med 1991; 173: 1099–1109.

45 Minegishi N, Ohta J, Yamagawa H, Suzuki N, Kawasumi S, Zhou Y et al. The mouse GATA-2 gene is expressed in the para-aortic splanchonpleura and aorta-gonads and mesonephros region. Blood 1999; 93: 4196–4207.

46 Suwabe N, Takahashi S, Nakano T, Yamamoto M. GATA-1 regulates growth and differentiation of definitive erythroid lineage cells during in vitro ES cell differentiation. Blood 1998; 92: 4108–4118.